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Background: The fine balance of Th17/Treg is crucial for maintenance of immune homeostasis. The objective of
this study was to investigate the balance of Th17/Treg and the expression of related cytokines in Uighur cervical
cancer patients.
Methods: Peripheral blood was collected from 65 cases of cervical cancer patients, 42 cases of cervical CIN patients
and 40 healthy people. Flow cytometry was used to detect the percentages of T cell subsets, including CD3+
T cells, CD4+ T cells, CD8+ T cells, Treg cells and Th17 cells. ELISA assay was conducted to detect expression levels
of TGF-β, IL-6, IL-10, IL-17, IL-23 and IFN-γ.
Results: There were no significant difference in the levels of CD3+ T cells, CD4+ T cells, CD8+ T cells, and the ratio
of CD4+/CD8+ among the cervical cancer group, the CIN group and the healthy control group. However, compared
with the healthy control group, the percentages of CD4+ CD25+ Treg, CD4+CD25+CD127- Treg, CD4+IL17+ Th17,
CD4+CD25+Foxp3+, CD4+CD25- Foxp3+, CD8+CD25+CD127-Treg and CD8+CD25+Foxp3 were significantly higher in
the cervical cancer group and the CIN group. Similar results were also found in the Th17/Treg ratio and the related
cytokines. There was no significant difference between the cervical cancer group and the CIN group. Additionally,
Th17 cell levels were positively correlated with IL-6, IL-23 and IL-17. Also, Treg cell levels were positively correlated
with TGF-β, IL-10 and IL-6. Contrarily, Treg cell levels and IFN-γ were negatively correlated.
Conclusions: Our data indicated that the Th17/Treg balance was broken in peripheral blood of cervical cancer
patients. Analysis of Th17/Treg balance may have a significant implication in diagnosing cervical cancer.
Virtual slides: The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1813823795931511
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The morbidity rate and mortality rate of cervical cancer
rank the second place in the female genital tract malig-
nancies. Annually there are nearly 500,000 new cases
worldwide and half of them die of cervical cancer [1].
Surgery and (or) radiotherapy are the most commonly
used treatments for cervical cancer. The interventional* Correspondence: 2332917439@qq.com
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reproduction in any medium, provided the orchemotherapy is also an effective adjuvant therapy.
However these methods are still limited. With the rapid
development of tumor immunology and molecular bio-
logy, biological therapy has become an important mea-
sure for the treatment of malignant tumors. In Xinjiang
Uygur women, the morbidity rate and mortality rate of
cervical cancer were 459/100000-590/100000 and 15.78/
100000, significantly higher than the other ethnic groups
living in the same environment. The onset age of cer-
vical cancer was also earlier than other ethnic minorities
in the country. Furthermore the mortality rate of cer-
vical cancer in Xinjiang Uygur women ranked the firsttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is urgent to study the Uygur cervical cancer-specific
diagnostic method and therapy.
Cervical cancer is primarily caused by persistent infec-
tion with high-risk human papilloma-virus (HPV). HPV
infection, in most cases, is self-limiting and can be eradi-
cated by humoral and cell-mediated immune response.
This suggests that immunoregulation may play an im-
portant role in cervical cancer carcinogenesis. However,
there is limited information on Th17/Treg and their
related cytokines in cervical cancer bearing hosts, espe-
cially in Uyghur women. Importantly, only a minority of
the cases progress to cervical precancerous lesions. And
the process from precancerous lesions to invasive cer-
vical cancer takes about ten years. Therefore, it is of
great importance to make effective screening of precur-
sor lesion. The most widely applied screening methods
are cytological examination and HPV test. Currently,
new methods have been implicated. Liu et al. [3] applied
the genomic amplification of the human telomerase gene
(hTERC) as a supplementary method to screen cervical
cancer in high-risk patients. For the detection of high-
grade cervical intraepithelial neoplasia (CIN), Chen et al.
[4] used the genomic amplification patterns of human
telomerase RNA gene and C-MYC. Monoclonal antibody
D2-40 against M2A antigen and p16 have also been used
as immunoreactive makers to identify cervical cancer
[5,6]. However, little is known about the diagnostic roles
of immune cells and cytokines in cervical cancer.
Studies have shown that the CD4+ T cell subsets in-
clude helper T cells type 1 (Th1), helper T cells type 2
(Th2), CD4+ CD25+ regulatory T cells (Treg) and helper
T cells 17 (Th17) [7,8]. Under different circumstances,
CD4+ T cells can differentiate into these cell subsets and
secret different cytokines to mediate immune response.
For example, under the induction of IL-12 and
interferon-γ (IFN-γ), CD4+ T cells can differentiate into
Th1 cells, and produce IFN-γ. With the induction of
IL-4, CD4+ T cells can differentiate into Th2 cells and
secrete IL-4, IL-5 and IL-13. With the induction of
transforming growth factor-β (TGF-β), CD4+ T cells can
differentiate into Treg cells, which secrete TGF-β and
express Forkhead family protein 3 (Foxp3). Under the
induction of the TGF-β and IL-6, CD4+ T cells can dif-
ferentiate into Th17 cells and produce IL-17, IL-21,
IL-23 and other cytokines. As a negative regulator, IL-10
has a strong immunosuppressive effect and plays a crit-
ical role in reducing the immune damage. By secreting
IL-10, Th2 cells can inhibit the function of Thl cells and
regulate the balance of Th1/Th2. In addition, IL-10 can
regulate autoimmune inflammatory damage such as EAE
and contribute to the role of anti-inflammatory by Treg
cells. In addition to Th2 and Treg cells, Th17 cells can
also secrete a small amount of IL-10.The discovery of Th17 cells derived from the study of
the mechanisms of autoimmune diseases. Th17 cells
mainly secrete IL-17 and play many roles in immune re-
sponse. They can promote the proliferation and differen-
tiation of a variety of cells. Also they are involved in the
proliferation, maturation and chemotactic activity of
neutrophils. Additionally they can co-stimulate the ac-
tivation of T cells and promote the maturation of
dendritic cells. Treg cells can negatively regulate the ac-
tivation and proliferation of autoreactive T cells. Hence
they are closely related to maintaining immune tole-
rance, preventing the occurrence of autoimmune dis-
eases and inhibiting anti-graft rejection and tumor
immunity. Previous studies reported that the immune
responses against tumor were mainly mediated by Thl
cells. If the Thl/Th2 ratio was imbalanced because of the
Th2 cells increase, the anti-tumor immune response of
the body would be severely weakened, leading to the ma-
lignant growth of the tumor. Current studies have found
that Treg cells and Th17 cells also played an important
role in anti-tumor immune response. Xiang et al. [9]
reported that the levels of Th17 cells and Treg cells were
imbalanced in inflammatory response and autoimmune
diseases. However whether this imbalance is involved in
the regulation of tumor immune is unknown and has
aroused much attention. The relationship between the
imbalance of Th17/Treg and tumor needs further inves-
tigation. In this study, we analyzed the percentages of
Th17 cells, Treg cells and FoxP3 positive T cells. We also
detected the expression levels of IL-6, IL-10, IL-17,
IL-23, IFN-γ and TGF-β. Our results provide a further
understanding of the differentiation status of immune
cells in cervical cancer of Uygur women.
Methods
Subjects
Sixty-five cases of cervical cancer patients who did not
undergo surgery and were enrolled in our hospital from
January 2009 to October 2011 were selected as the
Uygur cervical cancer group (UCC group). They were
aged between 36 to 60 years, with a mean age of 45.50 ±
6.12 years. Forty-two cases of cervical cancer patients
with intraepithelial lesions that did not undergo any
treatment were selected as the CIN group. They were
aged between 26 to 58 years, with an average age of
44.24 ± 5.67 years. Forty healthy volunteers who did
physical examination in our hospital at August 2010
were selected as the healthy control group (control).
They were aged between 24 to 66 years, with an average
age of 45.35 ± 6.17 years. There were no significant dif-
ferences in age among the three groups. None of the en-
rolled subjects had any of the following diseases:
diabetes, hypertension, cardiovascular disease, preg-
nancy, acute or chronic infectious disease and a history
Table 2 The clinical data of the cervical CIN patients







Note: Pathological characteristics of cervical cancer in patients of the CIN
group were shown.
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jects were summarized in Tables 1, 2 and 3. The hist-
ology and clinical stage of cervical cancer patients were
classified based on 2000FIGO installments. Conduct of
clinical trials for this study was approved by the Medical
Ethical Committee of First Affiliated Hospital of
Xinjiang Medical University. All participants signed the
informed consent before sampling.
Antibodies, reagents and instruments
Mouse anti-human antibody, fluorescein isothiocyanate
(FITC)-CD25 antibody, phycoerythrin (PE)-CD127 an-
tibody, phycoerythrin-cy5 (PE-cy5)-CD4 antibody, allo-
phycocyanin (APC)-CD3 antibody, phycoerythrin-cy7
(PE-Cy7)-CD8 antibody, PE- Foxp3 antibody and the
isotype control antibody were purchased from Beckman,
USA. PE-labeled IL-17A monoclonal antibody (clone No.
ebio64DEC17) was purchased from eBioscience, America.
ELISA kits for the detection of human TGF-β, IL-6,
IL-10, IL-17, IL-23 and IFN-γ were obtained from the
Bender MedSystems, Austria.
The flow cytometer was purchased from Becton
Dickinson, USA.
Sample preparation
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from peripheral blood by Ficoll-Hypaque densityTable 1 The clinical data of the Uyghur cervical cancer
patients
Characteristic Category N = 65




Histology type SCC 56(86)
ADC/ADSC 9(14)
Tumor differetiation Well 11(17)
Moderate 21(32)
Poor 33(51)
Lymph node metastases Positive 23(35)
Negative 42(65)
Tumor size(cm) < 4 31(48)
≥ 4 34(52)





Note: Pathological characteristics of cervical cancer in patients of the UCC
group were shown.centrifugation (2500 r/min for 20 minutes at room
temperature). PBMCs were re-suspended at a density of
2 × 106 cells/ml in Roswell Park Memorial Institute (RPMI)
media 1640 with GlutaMAX. The RPMI 1640 media were
supplemented with 100 U/ml penicillin, 100 μg/ml strepto-
mycin and 10% fetal calf serum (Gibco, USA).
Flow cytometric analysis
For analysis of Th17 cells, the cell suspension was stimu-
lated with 20 ng/ml phorbol 12-myristate-13-acetate and
1 μg/ml ionomycin in the presence of 2 mmol/ml
monensin (Sigma-Aldrich, USA) in 24-well plates. After
stimulating for 4 hours (37°C, 5% CO2), the cells were
collected and washed once in phosphate buffered saline
(PBS). The cells were then incubated with APC-CD3
and PE-Cy5-CD4 at 4°C for 30 minutes. After surface
staining, the cells were fixed and permeabilized accor-
ding to the manufacturer’s instruction, and then stained
with anti-human PE-IL-17.
For analysis of Treg cells, the cell suspension was
transferred into tubes and washed in PBS. Then the cellsTable 3 The clinical features of the three groups
Clinical features UCC group CIN group Control group









Smoking 7 5 4
Drinking alcohol 3 2 2
Diabetes 1 0 0




Acute infection 0 0 0
Chronic infection 0 2 0




Pregnancy 0 0 0
Note: Direct comparison of the clinical features of the subjects enrolled in
this study.
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and FITC-CD25 at 4°C for 30 minutes. Then some
of the cells were stained with PE-CD127. The other
cells were incubated with PE-Foxp3 after fixation
and permeabilization according to the manufacturer’s
instruction.
All stained cells were analyzed by flow cytometry
(FACSCalibur) and FlowJo software (Tristar, USA). In
the flow cytometry, the forward angle scattering light
(FSC) and side scattering light (SSC) were adjusted to
select the lymphocytes. Different cell subsets were
detected by different cell labeling and gating. Cellquest
software was used for data analysis and the percentage
of positive cells was recorded.
Enzyme-linked immunosorbent assay (ELISA)
Serum of all groups were collected and stored in −80°C
before analysis. ELISA assay was performed according to
the manufacture’s instructions of the ELISA kits (Bender
MedSystems, Austria). The OD value at 450 nm was
measured. The concentrations of TGF-β, and IL-6, IL-10,
IL-17, IL-23 and IFN-γ were calculated according to the
standard curve.
Statistical analysis
The experimental data were expressed as mean ± s.e.m.
and analyzed by SPSS17.0 software. The age difference
among groups was compared using the t test. The diffe-Figure 1 Analysis of CD3+ T cells, CD4+ T cells, CD8+ T cells and the C
blood samples were collected from 65 cases of cervical cancer patients, 42
cytometry was used to conduct this experiment. (A) Percentages of CD3+ T
UCC group, the cervical CIN group and the healthy control group. p > 0.05rence between the groups was analyzed by variance ana-
lysis. Correlation analysis was performed with Spearman
rank correlation analysis. A p value of less than 0.05 was
considered statistically significant.
Results
Percentages of T cells and T cell subsets in the peripheral
blood of the three groups show no significant difference
The percentages of T cells and T cell subsets in the peri-
pheral blood indicate the functional status of the
immune system. To check the immune function of the
three groups, we analyzed the levels of CD3+ T cells,
CD4+ T cells and CD8+ T cells, and the CD4+/CD8+ ra-
tio. The cells were analyzed by flow cytometry and the
quantitative results were shown in Figure 1. The per-
centages of CD3+ T cells in the UCC group, the CIN
group and the healthy control group were 52.80% ±
13.97%, 53.8% ± 14.07% and 55.56% ± 13.86%, respec-
tively. The percentages of CD4+ T cells in the UCC
group, the CIN group and the healthy control group
were 42.10% ± 8.22%, 43.33% ± 8.68% and 45.07% ±
9.52%, respectively. The percentages of CD8+ T cells in
the UCC group, the CIN group and the healthy control
group were 33.18% ± 8.35%, 30.03% ± 9.14% and 30.95% ±
9.20%, respectively. Statistically, for all the T cell subsets
(CD3+ T, CD4+ T and CD8+ T cells) detected, the di-
fferences among the three groups were not significant
(p > 0.05). In addition, the ratio of CD4+/CD8+ in theD4+/CD8+ ratio in the peripheral blood of three groups. Peripheral
cases of cervical CIN patients and 40 cases of healthy people. Flow
cells, CD4+ T cells and CD8+ T cells; (B) The ratio of CD4+/CD8+ in the
.
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were 1.56 ± 0.64, 1.62 ± 0.43 and 1.67 ± 0.26, respectively.
Also there was no significant difference among the three
groups (p > 0.05). These results suggest that the immune
function of the cervical cancer patients and the cervical
CIN patients was similar to that of the healthy individuals.
Percentages of Treg cells and Th17 cells are elevated in
cervical cancer patients and CIN patients
Percentages of Treg cells and Th17 cells in the peripheral
blood of the three groups were analyzed by flow cytometry.
Cells were labeled with different surface markers. The fol-
lowing subsets of CD4+CD25+Treg, CD4+CD25+CD127-
Treg, CD8+CD25+CD127-Treg, CD4+CD25+Foxp3+, CD4+
CD25-Foxp3+, CD8+CD25+Foxp3+ and CD4+IL17+Th17
cells were analyzed respectively. And the ratio of
TH17/Treg was also checked. Representative flow cy-
tometry results were shown in Figure 2 and the quanti-Figure 2 Flow cytometric analysis of Treg cells and Th17 cells in the p
collected from 65 cases of cervical cancer patients, 42 cases of cervical CIN
cytometric results were shown. The indicated percentages in each figure re
CD4+CD25+Treg cells in CD4+T cells; (B) Percentages of CD4+CD25+CD127lowTre
CD8+T cells; (D) Percentages of CD4+CD25+ FOXP3+Treg cells and CD4+CD25-F
in CD8+T cells; (F) Percentages of CD4+IL-17+Th17 cells in CD4+T cells.tative results were shown in Figure 3. As indicated in
Figures 2A and 3A, the percentages of CD4+CD25+Treg
cells in the UCC group and the cervical CIN group were
13.31% ± 2.02% and 12.75% ± 2.61%, statistically higher
than those in the control group (6.99% ± 1.62%) (p < 0.05).
There was no significant difference between the UCC
group and the CIN group (p > 0.05). Similarly, the percent-
ages of CD4+CD25+CD127-Treg cells (Figures 2B and
3B), CD8+CD25+CD127-Treg cells (Figures 2C and 3C),
CD4+CD25+Foxp3+ cells (Figures 2D and 3D), CD4+CD25-
Foxp3+ cells (Figures 2D and 3E), CD8+CD25+Foxp3+ cells
(Figures 2E and 3F) and CD4+IL17+Th17 cells (Figures 2F
and 3G) were also significantly higher in the UCC group
and the CIN group compared with the control group
(p < 0.05). No significant difference was found between the
UCC group and the CIN group (p > 0.05). The detailed data
of the percentages were illustrated in the representative
flow cytometric figures and listed in Table 4. In addition,eripheral blood of three groups. Peripheral blood samples were
patients and 40 cases of healthy people. Representative flow
presented the levels of the analyzed cell subsets. (A) Percentages of
g cells in CD4+T cells; (C) Percentages of CD8+CD25+CD127lowTreg cells in
OXP3+Treg in CD4+T cells; (E) Percentages of CD8+CD25+ FOXP3+Treg cells
Figure 3 Quantitative analysis of Treg cells and Th17 cells in the peripheral blood of three groups. Peripheral blood samples were
collected from 65 cases of cervical cancer patients, 42 cases of cervical CIN patients and 40 cases of healthy people. Quantitative results of the
flow cytometric analysis were shown. (A) Percentages of CD4+CD25+Treg cells in CD4+T cells; (B) Percentages of CD4+CD25+CD127lowTreg cells in
CD4+T cells; (C) Percentages of CD8+CD25+CD127lowTreg cells in CD8+T cells; (D) Percentages of CD4+CD25+ FOXP3+Treg cells in CD4+T cells;
(E) Percentages of CD4+CD25-FOXP3+Treg in CD4+T cells; (F) Percentages of CD8+CD25+ FOXP3+Treg cells in CD8+T cells; (G) Percentages of
CD4+IL-17+Th17 cells in CD4+T cells. (H) Ratio of Th17/ Treg in three groups. Each experiment was performed three times. Percentages of cells
in the UCC group and the cervical group were compared with those in the healthy control group. *p < 0.05.
Table 4 The proportions of Treg cells and Th17 cells of
the three groups
Percentages (%) of cells UCC group CIN group Control group
CD4+CD25+Treg 13.31 ± 2.02 12.75 ± 2.61 6.99 ± 1.62
CD4+CD25+ CD127-Treg 6.43 ± 1.04a 6.13 ± 1.23a 3.78 ± 0.70
CD8+CD25+CD127-Treg 3.01 ± 1.21 2.66 ± 1.45 1.73 ± 1.03
CD4+CD25+Foxp3+ 6.81 ± 1.03 6.35 ± 1.75 2.81 ± 1.41
CD4+CD25-Foxp3+ 3.52 ± 1.45 3.15 ± 1.38 1.53 ± 0.87
CD8+CD25+Foxp3+ Treg 0.81 ± 0.19 0.74 ± 0.23 0.27 ± 0.16
CD4+IL17+Th17 3.54 ± 1.44 3.29 ± 1.45 0.96 ± 0.54
Note: The quantitative results of flow cytometry analysis in Figure 2 were
shown in this Table.
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Treg ratio in the UCC group (0.26 ± 0.11) and the CIN
group (0.25 ± 0.12) were also significantly higher (p < 0.05).
Taken together, these data suggest that in cervical cancer
patients the levels Treg cells and Th17and the ratio of
TH17/Treg were significantly changed.
Expression levels of TGF-β, IFN-γ, IL-6, IL-10, IL-17
and IL-23 are elevated in cervical cancer patients and
CIN patients.
ELISA assay was performed to measure the expression
levels of the cytokines (including TGF-β, IFN-γ, IL-6,
IL-10, IL-17 and IL-23) in the serum and the quantita-
tive results were shown in Figure 4. The levels of TGF-β
Figure 4 Detection of related cytokines. Peripheral blood samples were collected from 65 cases of cervical cancer patients, 42 cases of cervical
CIN patients and 40 cases of healthy people. ELISA assay was performed to detect the expression levels of related cytokines in the serum of the
three groups. (A) levels of TGF-β; (B) levels of IFN-γ; (C) levels of IL-6; (D) levels of IL-10; (E) levels of IL-17; (F) levels of IL-23. Each experiment was
performed three times. Levels of cytokines in the UCC group and the cervical group were compared with those in the healthy control
group. *p < 0.05.
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trol group were 49000 ± 12910 pg/mL, 46000 ±
11480 pg/mL and 22000 ± 8140 pg/mL, respectively
(Figure 4A). The levels of IFN-γ in the UCC group, the
CIN group and the healthy control group were 7.75 ±
3.32 pg/mL, 8.47 ± 3.35 pg/mL and 14.25 ± 4.95 pg/mL,
respectively (Figure 4B). The levels of IL-6 in the UCC
group, the CIN group and the healthy control group
were 46.38 ± 14.38 pg/mL, 42.52 ± 14.78 pg/mL and
6.87 ± 3.13 pg/mL, respectively (Figure 4C). The levels of
IL-10 in the UCC group, the CIN group and the healthy
control group were 121.28 ± 30.09 pg/mL, 115.21 ±
16.74 pg/mL and 23.31 ± 9.79 pg/mL, respectively
(Figure 4D). The levels of IL-17 in the UCC group,
the CIN group and the healthy control group were
195.73 ± 23.48 pg/mL,189.74 ± 20.82 pg/mL and 58.37 ±
18.27 pg/mL, respectively (Figure 4E). The levels of
IL-23 in the UCC group, the CIN group and the healthy
control group were 125.55 ± 19.08 pg/mL, 119.43 ±
23.79 pg/mL and 26.67 ± 8.17 pg/mL, respectively
(Figure 4F). Statistically, compared with the healthy
control group, the expression levels of these cytokines
in the UCC group and the CIN group were significantly
higher (p < 0.05). Meanwhile, there was no significant
difference between the UCC group and the CIN group(p > 0.05). Collectively, the expression levels of TGF-β,
IFN-γ, IL-6, IL-10, IL-17 and IL-23 were up-regulated in
cervical cancer patients. And these results suggest that
immune response in cervical cancer patients was
suppressed.Correlation analysis
As mentioned above, percentages of Th17 cells and Treg
cells were increased in cervical cancer patients. So were
the levels of TGF-β, IFN-γ, IL-6, IL-10, IL-17 and IL-23
cytokines. In order to check whether these two eleva-
tions were correlated to each other, we did the correla-
tion analysis in the UCC group. As shown in Figure 5,
there was a positive correlation between percentages of
Th17 cells and levels of IL-6, IL-23 and IL-17 cytokines
(r = 0.874, p < 0.01, Figure 5A; r = 0.720, p < 0.01,
Figure 5B; r = 0.823, p < 0.01, Figure 5C). Similarly, as
shown in Figure 6A, C and D, there was a positive cor-
relation between percentages of Treg cells and levels of
TGF-β, IL-10 and IL-6 cytokines (r = 0.874, p < 0.01,
Figure 6A; r = 0.720, p < 0.01, Figure 6C; r = 0.823,
p < 0.01). On the contrary, there was a negative correl-
ation between percentages of Treg cells and levels of
IFN-γ cytokine (r = −0.567, p < 0.01, Figure 6B).
Figure 5 Correlation analysis of levels of Th17 cells and levels of IL-6, IL-23 and IL-17 in the UCC group. Correlation assay was conducted
using the Spearman rank correlation test. (A) Correlation analysis between Th17 and IL-6; (B) Correlation analysis between Th17 and IL-23;
(C) Correlation analysis between Th17 and IL-17.
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In our study, by studying the Treg/ Th17 balance and
the related cytokines, we systematically investigated the
cervical tumor immunology of Uygur women. The sam-
ples consisted of 65 cervical cancer patients, 42 cervical
CIN patients and 40 healthy volunteers. The PBMCs
were collected and stained with different cell surface
markers before cytometric analysis. Levels of related cy-
tokines were detected by ELISA kits. We hope that our
findings would provide further experimental data for
cervical tumor immunology.
Firstly, we analyzed the total percentages of peripheral
CD3+ T cells, CD4+ T cells and CD8+ T cells. Our results
showed that there were no significant differences in the
total percentages of peripheral CD3+ T cells, CD4+ T cells
and CD8+ T cells, and the ratio of CD4+/CD8+ (p > 0.05).
These results showed that the T cell subsets of CD4+ and
CD8+ cells in cancer patients were not lower than those in
healthy individuals.
Then we detected the percentages of Treg cells. Treg
cells are a kind of suppressor immune cells and play im-
portant roles in immune tolerance and homeostasis.
Studies have shown that percentages of Treg cells in-
creased in advanced tumor patients. This increase of
Treg cells was correlated to the decrease of mortality.
Dannull J et al. [10] depleted Treg cells by anti-CD25
antibody in tumor bearing mice. They found that therewere effective anti-tumor immune responses in these
mice. These results indicate a suppressive role of Treg
cells in anti-tumor immune response. In addition, Liu
et al. [11] reported that CD127 was one of the surface
markers of Treg cells. In our study, we found that the
percentages of CD4+CD25+CD127lo/- Treg in CD4+ T cells
in the UCC group, the CIN group and the control
group were (6.43 ± 1.04)%, (6.13 ± 1.23)% and (3.78 ±
0.70)%, respectively. Compared with the control group,
the percentages of CD4+CD25+CD127lo/- Treg in the
UCC group and the CIN group were significantly
higher (p < 0.05). There was no significant difference
between the UCC group and the CIN group
(p > 0.05). Thus we speculate that CD4+CD25+
CD127lo/- Treg cells may play an important role in
the development of cervical cancer. In cervical cancer
patients, Treg cell-mediated immune tolerance may
be closely related to tumor growth, and may be dir-
ectly involved in tumorigenesis. Also there was a
slight increase of the CD4+CD25+CD127lo/- Treg cells
in the UCC group compared with those in the CIN
group. This data further suggest that with the progression
of cervical cancer, the number of CD4+CD25+CD127lo/-
Treg cells was gradually increased. This increase fur-
ther suppressed the immune response and weakened
the anti-tumor response, leading to the growth and me-
tastasis of the tumor.
Figure 6 Correlation analysis of levels of Treg cells and levels of TGF-β, IFN-γ, IL-10 and IL-6 in the UCC group. Correlation analysis was
performed by the Spearman rank correlation test. (A) Correlation analysis between Treg and TGF-β; (B) Correlation analysis between Treg and
IFN-γ; (C) Correlation analysis between Treg and IL-10; (D) Correlation analysis between Treg and IL-6.
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percentages of CD4+Foxp3+Treg cells in the peripheral
blood of pancreatic cancer patients were significantly
higher. Similarly, CD4+Foxp3+Treg cells were also higher
in prostate cancer bearing mice and glioma tumor bear-
ing mice [13,14]. These results suggest that CD4+Foxp3+
Treg cell levels were closely related with tumors. Naive
CD4+ T cells can be transformed into CD4+ CD25+ T cells
by introducing Foxp3. CD4+ CD25+ T cells lack of
Foxp3 did not induce the suppressor function [15]. Our
study showed that the CD4+Foxp3+ Treg cells in the
UCC group and the healthy control group were (3.52 ±
1.45)% and (1.53 ± 0.87)%. And the CD4+CD25+Foxp3+
Treg in the UCC group and the healthy control group
were (6.81 ± 1.03)% and (2.81 ± 1.41)%. Statistically, the
CD4+Foxp3+ Treg cells and CD4+CD25+Foxp3+ Treg
cells in UCC group were significantly higher than the
healthy control group (p <0.05). The same significant
difference was also found between the cervical CIN
group and the healthy control group. Meanwhile there
was no significant difference between the UCC group
and the cervical CIN group. However the percentages of
Foxp3+ Treg cells in the cervical CIN group were
slightly higher than the UCC group, indicating that with
the progression of cancer, percentages of Foxp3+ Treg
cells gradually increased. It is known that Foxp3+ Tregcells could inhibit anti-tumor function of CD8+ T cells
in vitro. Hence it is reasonable to speculate that up-
regulation of Foxp3+ Treg cells in cervical CIN and cervical
cancer patients will lead to weakened immune surveillance
function. Therefore Foxp3+ Treg cells up-regulation may
be the underlying mechanisms of cervical cancer genesis
and development.
Studies found that in prostate cancer [16,17] and colo-
rectal cancer [18] patients, the numbers CD8+CD25+
Foxp3+ T cells in the peripheral blood of patients and
the local regions of cancer increased. CD8+CD25+
CD127lo/- Treg cells have a similar function. In this
study, the percentages of CD8+CD25+Foxp3+ T cells in
the UCC group and the control group were (0.81 ±
0.19)% and (0.27 ± 0.16)%. The percentages of CD8+
CD25+CD127lo/- Treg cells in the UCC group and the
control group were (3.01 ± 1.21)% and (1.73 ± 1.03)%, re-
spectively. Statistically, the CD8+CD25+Foxp3+ T cells
and CD8+CD25+CD127lo/- Treg cells in UCC group were
significantly higher than the control group (p <0.05). Si-
milarly the statistically significant difference was also
found between the patients of the CIN group and indivi-
duals of the control group (p < 0.05). No statistically sig-
nificant difference was found between the UCC group and
the cervical CIN group (p > 0.05). However, with the de-
velopment of the disease, the levels of these two cells in
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increased. CD8+CD25+ Treg cells are newly discovered
regulatory T cells and have immunosuppressive effects,
resulting in an immunocompromised state of patient. In
our study, we found that CD8+CD25+ Treg cells were up-
regulated in cervical cancer patients, suggesting that CD8+
CD25+ Treg cells may play a role in the inducement and
maintenance of immune tolerance in cervical cancer pa-
tients. Treatment targeting CD8+CD25+ Treg cells may be
a promising measure in the future immunotherapy for
cervical cancer.
Several studies have shown that Th17 cells and Treg
cells were closely related with malignant tumors such as
gastric cancer, ovarian cancer and colon cancer [19-22].
We found similar results in this study. We found that
the percentages of Th17 cells in the UCC group (3.54% ±
1.44%) were significantly higher than those in the control
group (0.96% ± 0.54%) (p < 0.05). Also statistically signifi-
cant difference was also found between the cervical CIN
group and the control group. At the same time, there was
no significant difference between the UCC group and the
cervical CIN group. Yet the percentages of Th17 cells in-
creased gradually with the progression of cancer. So was
the ratio of TH17/Treg. Beriou et al. [23] found that in
the presence of strong TCR signaling and APC, Treg cells
could secrete IL-17. Furthermore, in the tumor mi-
croenvironment producing IL-17, Treg cells could be
transformed into Th17 cells, which further amplified the
inflammatory response. The transformation between the
Treg cells and Th17 cells may determine the growth and
regression of tumor.
Cytokines are important mediators of immune re-
sponses, including immune responses in tumor environ-
ment. During tumorigenesis, the roles of some cytokines
are ambivalent. For example, TGF-β could promote
tumor growth through diminishing the production of
IFN-γ and stimulating Treg cells. On the other hand, cy-
tokines of TGF-β, IL-6 and IL-23 could promote the de-
velopment of Th17 cells, which could enhance the
immune response in the tumor environment and inhibit
tumor growth. As mentioned above, we detected the
changes in the percentages of Th17 and Treg cells in the
peripheral blood of cervical cancer patients. To further
investigate the role of cytokines in cervical cancer bear-
ing patients, we measured the related cytokines of Th17
and Treg cells in the peripheral blood of cervical cancer
patients. The following cytokines of TGF-β, IL-6, IL-10,
IL-17, IL-23 and IFN-γ were measured. Also, the corre-
lation of these cytokines with Th17 and Treg cells was
analyzed in the UCC group.
It is known that IFN-γ is a tumor-killing cytokine pro-
duced by CTL and NK cells. CTL and NK cells are the
primary tumor immunity cells in the body. In this study,
the expression levels of IFN-γ were also analyzed. Wefound that IFN-γ levels in patients with cervical cancer
and cervical CIN were significantly lower than those in
the control group. Also IFN-γ levels were negatively cor-
related with CD4+CD25+CD127lo/- Treg cell levels. This
data suggest that Treg cells may suppress CTL and NK
cells to produce IFN-γ cytokine.
Th17 cells could secrete IL-17, which could promote
tumor angiogenesis and further promote tumorigenesis
and development. One in vivo study transfected NSCLC
cells with IL-17 expressing plasmids and then trans-
planted these cells into SCID mice. They found that tu-
mors formed by these cells growed much faster [24].
This result further illustrates that IL-17’s role of promot-
ing angiogenesis was through increasing the chemotaxis
of vascular endothelial. Our results were consistent with
this study. We found that levels of TGF-β, IL-6, IL-10,
IL −17 and IL-23 in patients with cervical cancer and
cervical CIN were significantly higher than those in the
control group. Furthermore there was a positive corre-
lation between the percentages of Th17 cells (r = 0.874,
p < 0.01; r = 0.720, p < 0.01; r = 0.823, p < 0.01) and the
levels of IL-6, IL-23 and IL-17. And the percentages of
Treg cells was positively correlated with levels of TGF-β,
IL-10 and IL-6 (r = 0.690, p < 0.01; r = 0.827, p < 0.01;
r = 0.283, p < 0.05). These data suggest that cytokines of
TGF-β, IL-6, IL-17 and IL-23 promoted the imbalance
of Th17/Treg ratio. The increase of these cytokines may
reduce the body’s immune function and promote tumor
development by affecting the Th17/Treg ratio. Thus
these changes might be the possible reasons that pro-
moted the development of cervical cancer.Conclusions
In summary, our study concluded that elevations of
CD4+CD25+CD127lo/-Treg, Foxp3+ Treg, CD8+ Treg and
Th17 cells exsit in peripheral blood of Uygur patients with
cervical cancer. And these changes may be one of the
reasons for low immune function. And one of the possible
immune mechanisms for Uygur cervical cancer was
TH17/Treg imbalance. In the future, enhancing the body’s
immune surveillance function could be done through
reducing the levels of CD4+CD25+CD127lo/-Treg, Foxp3+
Treg, CD8+ Treg and Th17 cells or reversing their pheno-
types, or correcting the imbalance of Th17/Treg ratio.
And this may provide a new therapeutic approach for
improving the anti-tumor immunity.Abbreviations
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